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Human and canine cancer share similarities such as 
genetic and molecular aspects, biological complexity, 
tumor epidemiology, and targeted therapeutic treat-
ment. Lack of good animal models for human adenoviro-
therapy has spurred the use of canine adenovirus 2-based 
oncolytic viruses. We have constructed a canine oncolytic 
virus that mimics the characteristics of our previously 
published human adenovirus ICOVIR17: expression of 
E1a controlled by E2F sites, deletion of the pRb-binding 
site of E1a, insertion of an RGD integrin-binding motif at 
the fiber Knob, and expression of hyaluronidase under 
the major late promoter/IIIa protein splicing acceptor 
control. Preclinical studies showed selectivity, increased 
cytotoxicity, and strong hyaluronidase activity. Intratu-
moral treatment of canine osteosarcoma and melanoma 
xenografts in mice resulted in inhibition of tumor growth 
and prolonged survival. Moreover, we treated six dogs 
with different tumor types, including one adenoma, two 
osteosarcomas, one mastocitoma, one fibrosarcoma, 
and one neuroendocrine hepatic carcinoma. No virus-
associated adverse effects were observed, but toxicity 
associated to tumor lysis, including disseminated intra-
vascular coagulation and systemic failure, was found in 
one case. Two partial responses and two stable diseases 
warrant additional clinical testing.
Received 18 April 2013; accepted 14 January 2014; advance online  
publication 4 March 2014. doi:10.1038/mt.2014.7
INTRODUCTION
In dogs as in humans, cancer is a major cause of mortality.1,2 More 
than four million new cancer diagnoses in pet dogs are expected 
per year.2 Virotherapy with conditionally replicative viruses in 
general, adenovirus (Ad) in particular is a promising therapy for 
cancer.3 Several animal species have been used as models for can-
cer therapy with human Ad (hAd).4 Often, xenograft-implanted 
nude mice are used to analyze efficacy and immune-competent 
mice are used for toxicity.5 However, the mouse is nonpermissive 
to hAd replication. Syrian Hamster has been suggested as a better 
model than mouse6 because it is semipermissive to hAd replica-
tion. Despite this advantage, hamster tumors are still engrafted 
showing a structure and progression different from that of spon-
taneous tumors. These fundamental differences lead to poor pre-
clinical to clinical correlations in efficacy and, occasionally, to 
nonexpected toxicity events.7
HAd5 replication has been demonstrated in established and 
primary canine cell lines8 pointing the dog as a good model to ana-
lyze preclinically human conditionally replicative Ads (CRAds). 
Moreover, an immune-stimulatory human vector (AdCD40L) has 
been administered in canine melanoma patients with promising 
results, warranting future application in human patients.9 In this 
context, the dog has been suggested as an ideal syngeneic model 
for virotherapy. Pet dogs develop cancer spontaneously due to an 
increased life expectancy and an exposure to similar environmen-
tal conditions to humans.10 Canine patients provide an outbred 
genetic background and they are genetically closer to humans 
than laboratory rodents.11 Moreover, cancer therapy occurs in 
the presence of an immune system and the biologic behavior and 
clinical presentation of certain canine tumors are similar to their 
human counterparts.2 Dogs are routinely vaccinated with canine 
adenovirus type 2 (CAV2)-based vaccines12 to elicit a crossreacting 
protection against CAV1.13 Thus, dogs have variable titers of spe-
cific neutralizing antibodies resembling human population, with 
implications for the efficacy and safety of the treatment.14 With 
the aforementioned, treatment of pet-dog patients with a canine 
CRAd (cCRAd) based on CAV2 would fulfill the requirements 
of a good predictive model of human cancer treatment.15 On the 
other hand, cCRAds may benefit canine cancer patients as nearly 
all cancer treatments for dogs are palliative1 and around 50% of 
dogs older than 10 years diagnosed with cancer die because of it.2 
Developing new cancer therapies for canine patients may bring 
veterinary medicine at the forefront of cancer therapy research.
With this aim, an osteocalcin (OC) promoter-controlled 
cCRAd (OCCAV) has been developed and used to treat canine 
xenografts.16,17 OCCAV has proven safe in laboratory Beagles 
intravenously injected with up to 2 × 1012 viral particles (vp)18: only 
one Grade 4 neutropenia was described, with no other important 













© The American Society of Gene & Cell Therapy
Correspondence: Ramon Alemany, Translational Research Laboratory, IDIBELL-Institut Català d’Oncologia, Av Gran Via de l’Hospitalet 199–203, 
L’Hospitalet de Llobregat, 08907 Barcelona, Spain. E-mail: ralemany@iconcologia.net
A pRb-responsive, RGD-modified, and 
Hyaluronidase-armed Canine Oncolytic Adenovirus 
for Application in Veterinary Oncology
Eduardo Laborda1,2, Cristina Puig-Saus1, Alba Rodriguez-García1, Rafael Moreno1, Manel Cascalló3, 
Josep Pastor4 and Ramon Alemany1
1Translational Research Laboratory, IDIBELL-Institut Català d’Oncologia, Barcelona, Spain; 2Biochemistry and Molecular Biology Department, 
 Autonomous University of Barcelona, Barcelona, Spain; 3VCN Biosciences, Barcelona, Spain; 4Animal Medicine and Surgery Department, Fundació 
Hospital Clínic Veterinari, Autonomous University of Barcelona, Barcelona, Spain
Oncolytics
986 www.moleculartherapy.org vol. 22 no. 5, 986–998 may 2014
© The American Society of Gene & Cell Therapy
Hyaluronidase-armed Canine Oncolytic Adenovirus
hepatic destruction even when biodistribution pointed out these 
organs as the main targeted tissues. However, OCCAV efficacy in 
tumor-suffering dogs remains to be studied and the selective rep-
lication in OC-expressing cells will limit the number of patients 
eligible for treatment.
Our group has previously generated ICOVIR17, an oncolytic 
Ad based on hAd5, with good results in preclinical studies.19 In the 
present study, we developed ICOCAV17, a CAV2-based cCRAd 
with similar characteristics to ICOVIR17, and two parental 
viruses, CAV2RGD and ICOCAV15, homologous to their human 
counterparts AdwtRGD and ICOVIR15, respectively.20,21 In vitro 
assays showed functional bioactivity of cCRAds and preclinical 
studies in tumor-harboring nude mice proved intratumoral injec-
tion as a safe and effective administration route. However, intrave-
nous toxicity in mice showed marked thrombocytopenia and loss 
of body weight. Thus, the intratumoral route was chosen for the 
treatment of six canine patients with ICOCAV17. Results include 
two partial responses (PR), two stable diseases, and two progres-
sive diseases.
RESULTS
In vitro characterization of cell lines and cCRAds
A schematic representation of the viruses used in this study is shown 
in Figure 1a. All viruses rendered similar yields (9,000 to 10,090 
Figure 1 Adenoviruses and cells used in this study and in vitro characterization. (a) Schematic representation of viruses used in this study. CAV2 
is the canine wild-type virus serotype 2. CAV2RGD contains an RGD motif (FiberRGD) in the HI-loop of the CAV2 fiber. ICOCAV15 and ICOCAV17 
are canine conditionally replicative adenoviruses, based on CAV2RGD, in which the endogenous E1a promoter have been modified inserting four 
palindromic E2F-binding sites and one Sp-I-binding site (403p) at the 403 nucleotide position of the virus genome, 21 base pairs of E1a region 
(E1aΔ21) homologous to Δ24 in human oncolytic adenoviruses have been deleted. ICOCAV17 is armed with the human PH20 hyaluronidase (PH20) 
under the control of the canine IIIa protein Splicing Acceptor (IIIaSA). MLP, Major late promoter; pA, polyadenylation signal. (b) Western blot of 
pRb in canine tumor cells and dog epidermal keratinocytes (DEK). Both hypophosphorylated (pRb) and hyperphosphorylated (ppRb) forms of the 
protein were resolved. Abrams cell line expressed low levels of ppRb. α-Tubulin was used as loading control. (c) Comparison of infectivity between 
CAV2 and CAV2RGD in four canine tumor cell lines. Abrams, 17CM98, D17, and CML1 cells were infected with an equal number of viral particles 
per cell of each virus using two different doses. Immune staining against viral hexon protein was performed 24 hours after infection, and the number 
of infected cells counted. The ratio between CAV2RGD and CAV2 of three independent assay results ± SD is shown. (d) ICOCAV15 total production 
yields in a cycle-arrested nontumor canine cell line. DEK were seeded in 24-wells plates. After 20 days in confluence, DEK were infected with 8 trans-
ducing units (tu)/cell of CAV2RGD or ICOCAV15. Two days postinfection, total virus production was measured. Three independent assay results ± SD 
are shown. (e) Virus production of ICOCAV15 in tumor cells. Different tumor cell lines were infected with a dose of virus that resulted in >80% 
transduction (20 tu/cell for D17 and CML1 and 30 tu/cell for Abrams and 17CM98). Two days after infection, total virus production was measured 
in triplicate. Results ± SD are shown. (f) Hyaluronidase expression in cells infected with ICOCAV17. DK28Cre cells were infected with ICOCAV15 or 
ICOCAV17 with 20 tu/cell. After 48 hours, supernatants from infected cells were incubated with a solution of Hyaluronan (HA) for 0, 1, 2, 3, or 4 
hours and analyzed. Four samples with known concentration of purified hyaluronidase were used as references. HA degradation was measured by 
absorbance (600 nm). #Statistical significance between CAV2 and CAV2RGD (P < 0.05) by two-tailed unpaired Student’s t-test; *Statistical significance 
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vp/cell) in DK28Cre cells.22 To test the function of these cCRAds, in 
vitro assays were performed in four canine tumor cell lines. Abrams 
and D17 (pulmonary metastasis) derive from osteosarcoma (OS),23 
and 17CM98 and CML1 from melanoma.24 Dog epidermal kerati-
nocytes (DEK) were used as nontumor control cells. Studies point 
pRb pathway as necessary to cause cancer.25,26 We characterized pRb 
status of the cell lines used in this study by western blot (Figure 1b). 
Tumor cells contained hyperphosphorylated pRb (ppRb). In con-
trast, pRb from DEK was hypophosphorylated (pRb). Additionally, 
tumor cells were analyzed for expression of Coxsackie virus and 
adenovirus receptor (CAR) (data not shown). All cells had detect-
able levels of CAR. CML1 and D17 expressed similar levels to 
DK28Cre, while 17CM98 expressed lower levels and Abrams 
expressed even higher levels than DK28Cre. The insertion of RGD 
at the fiber HI-loop of hAds enhances infectivity and allows the 
virus to infect cells CAR independently.20,27 Similarly, CAV2RGD 
showed enhanced infectivity compared to CAV2 (Figure 1c). When 
we infected cells with a dose of 20 vp/cell for Abrams, 10 vp/cell for 
17CM98, 2 vp/cell for D17, and 6 vp/cell for CML1, the infectiv-
ity was increased 7.4 times (P = 0.008), 3.4 times (P = 0.04), and 2 
times (P = 0.03) in Abrams, 17CM98, and D17 cells, respectively. 
When infecting with a fivefold higher dose for Abrams, 17CM98, 
and D17 and a twofold higher dose for CML1, the infectivity was 
increased 1.4 times (P = 0.03), 1.15 times (P = 0.2), and 1.7 times 
(P = 0.009) in Abrams, 17CM98, and D17 cells, respectively. No 
differences were seen in CML1 cells at any dose. To test E2F-driven 
selectivity, progeny virus production was analyzed in tumor cells 
and arrested28 DEK. In DEK, the progeny production of ICOCAV15 
showed a decrease of 84% (P = 0.03) compared with the parental 
virus CAV2RGD (Figure 1d). Conversely, virus progeny produc-
tion was increased for ICOCAV15 compared with CAV2RGD 
in two out of four tumor cell lines (CML1 (P = 0.008) and D17 
(P = 0.02)), and a trend for improved production was observed in the 
other two cell lines (Abrams and 17CM98; Figure 1e). To confirm 
the activity of the hyaluronidase of ICOCAV17, a hyaluronic acid 
(HA) degradation assay29 was performed (Figure 1f). Supernatants 
(SN) from cells infected with ICOCAV17 degraded HA to an 
equivalent level of 4 units/ml of hyaluronidase, while ICOCAV15 
SN did not degrade HA at all. Finally, cytotoxicity was analyzed at 
days 6–8 comparing all viruses simultaneously (Figure 2). Under 
the conditions of time and transducing units (tu)/cell used, CAV2 
was not able to induce cytotoxicity (evidence of cytopathic effect) 
in Abrams and 17CM98 cells, even at a dose of 2,000 tu/cell. In 
D17 cells, CAV2RGD decreased the IC50 (amount of virus needed 
to reduce the cell culture viability by 50%) 1.9-fold (P = 0.032) com-
pared to CAV2. The E2F-binding sites rendered ICOCAV15 more 
Figure 2 Comparative cytotoxicity of canine viruses in four canine tumor cell lines. Infection with the indicated viruses, at doses ranging from 
2,000 to 0.01 transducing units (tu)/cell for Abrams, CML1, and 17CM98 or from 500 to 0.001 tu/cell for D17 was performed. The IC50 values (tu/cell 
needed to reduce by 50% the cell viability) at days 6–8 after infection are shown. Three different replicates were quantified for each cell line. Mean ± 
SD are plotted. IC50 →∞ for CAV2 at 17CM98 and Abrams cells indicates estimated values of IC50 over 106 tu/cell. *Significant (P < 0.05) compared 
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cytotoxic decreasing the IC50 by 3.7 times (P = 0.013), 7.2 times (P 
= 0.0009), and 4 times (P = 0.005) in CML1, D17, and 17CM98, 
respectively, compared to CAV2RGD. ICOCAV17 showed simi-
lar IC50 values to ICOCAV15. No differences between CAV2RGD, 
ICOCAV15, and ICOCAV17 were seen in Abrams cells.
Toxicity and biodistribution profile of canine 
adenoviruses after systemic administration in Balb/C 
immunocompetent mice
We had previously determined a tolerable dose for wild-type 
viruses (CAV2 and CAV2RGD) and a peak of body weight loss 
at day 2 after systemic administration (data not shown). Thus, 
mice were intravenously injected with 1 × 1011 vp of ICOCAV17 
or control viruses. Body weight was monitored daily and over-
all survival, liver enzymes (aspartate aminotransferase and ala-
nine aminotransferase), and hematology were determined at day 
3 after viral injection. At that time, animals were sacrificed and 
organs of groups injected with CAV2 and CAV2RGD were col-
lected and analyzed for presence of virus.
As expected, weight loss showed a peak of toxicity 48 hours 
postinjection for all viruses (Figure 3a). No animal died or lost 
more than 10% of its body weight. Viruses with the RGD motif 
in the capsid induced a significant decrease of body weight com-
pared to CAV2. Moreover, animals injected with ICOCAV15 
or ICOCAV17 had a slower recovery than those injected with 
CAV2RGD. Hematology analysis showed a dramatic decrease 
in platelets for all viruses (Figure 3b). Compared to phosphate-
buffered saline, all viruses induced a significant lymphopenia 
and a modest but significant increase of basophils, whereas only 
CAV2RGD and ICOCAV17 decreased monocytes significantly 
(Figure 3c).
Although a mild increase of liver enzymes was observed, none 
of the viruses increased significantly alanine aminotransferase or 
aspartate aminotransferase compared to PBS group (Figure 3d), 
consistent with the biodistribution results, where we did not 
find a marked liver tropism (Figure 3e). Instead, CAV2 and 
CAV2RGD showed a heterogeneous tropism. The spleen, lungs, 
liver, and kidney showed the highest concentrations of CAV2 and 
Figure 3 Toxicity and biodistribution profile after systemic administration of canine adenoviruses in immunocompetent mice. Balb/C immu-
nocompetent mice were injected intravenously with PBS or 1 × 1011 viral particles of CAV2, CAV2RGD, ICOCAV15, or ICOCAV17. The average values 
for (a) percentage of body weight variation during all the experiment and (b) platelet concentration, (c) leukocyte concentration, and (d) serum 
transaminases at day 3 after administration. (e) Biodistribution of CAV2 and CAV2RGD in mice tissues. Tissues were harvested 3 days after administra-
tion, snap frozen, and quantitatibe polymerase chain reaction assayed for the presence of viruses. Results are reported as viral genomes per milligram 
of tissue. ($) Blood concentration is reported as viral genomes per milliliter of blood. Mean values ± SD of n = 5 mice/group are depicted. *Statistical 
significance compared with groups injected with viruses (P < 0.05) by two-tailed unpaired Student’s t-test. #Statistical significance compared with 
CAV2 (P < 0.05) by two-tailed unpaired Student’s t-test. §Statistical significance compared with CAV2RGD (P < 0.05) by two-tailed unpaired Student’s 
t-test.·Statistical significance compared with PBS (P < 0.05) by two-tailed unpaired Student’s t-test. ALT, alanine aminotransferase; AST, aspartate 
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CAV2RGD (vp/mg of tissue and vp/ng of total DNA), whereas 
the liver showed the highest absolute amount of viral genomes 
(Supplementary Table S1). The levels of CAV2RGD were higher 
than those of CAV2 in the testis, heart, lungs, and kidneys. The 
viremia at day 3 was 100-fold higher for CAV2RGD compared 
with CAV2.
ICOCAV17 oncolytic potency in two xenograft 
models
We evaluated ICOCAV17 efficacy in melanoma and OS tumor 
models (Figure 4), two of the most common and devastating 
cancers in dogs.30 Nude mice harboring CML1 or Abrams tumors 
were injected intratumorally three times (on days 0, 7, and 14) 
with PBS or a dose of 1 × 1010 vp/tumor of each virus. Intratumoral 
injections did not decrease animal weight. In Abrams, ICOCAV17 
decreased tumor volume at the end of the experiment compared to 
all other groups (1.52-fold (P = 0.038) compared to PBS, 1.91-fold 
(P = 0.039) compared to CAV2, 1.87-fold (P = 0.006) compared to 
CAV2RGD, and 1.67-fold (P = 0.01) compared to ICOCAV15). In 
CML1, ICOCAV17 reduced tumor volume fivefold (P = 0.04) and 
2.7-fold (P = 0.002) compared to PBS and CAV2, respectively, at 
the end of the experiment (day 21 for PBS and day 26 for CAV2). 
Although differences in tumor volume between ICOCAV15 and 
PBS groups did not reach statistical significance in CML1, they 
did when percentage of tumor growth was analyzed at days 7 (P 
= 0.02) and 12 (P = 0.03) (data not shown). ICOCAV17 injection 
increased the survival of Abrams tumor-bearing mice compared 
to PBS (P = 0.044), CAV2 (P = 0.009), CAV2RGD (P = 0.004), 
and ICOCAV15 (P = 0.005), and compared to PBS (P = 0.01) and 
CAV2 (P = 0.004) in CML1 tumor-bearing mice. ICOCAV15 
prolonged (P = 0.058) the mean survival from 13 and 15 days to 
20.5 days, compared to PBS and CAV2 groups, respectively, in 
the CML1 model. Staining of tumors against late Ad proteins was 
performed at the end of the experiment (Supplementary Figure 
S1 and Supplementary Materials and Methods). We were able 
to detect virus in 1 or 2 tumors from each group and a trend for 
increased dissemination of ICOCAV17 compared with the other 
groups was observed, primarily in Abrams tumors. After efficacy 
and toxicity studies in mice, six canine patients were enrolled in 
an investigational trial with ICOCAV17 (see Table 1 for a sum-
mary of all six cases):
Clinical case I. A 14-year-old entire male Husky that had re-
ceived surgery 2 years before to remove a sweat gland adenoma, 
was admitted to the Veterinary Hospital with a mass located at 
the prepuce skin that caused dysuria. Infiltrative sweat gland ad-
enoma was diagnosed by fine needle aspiration. Due to the poor 
general condition of the dog and poor benefit of second-line che-
motherapy for recurrent sweat gland adenoma,31 chemotherapy 
and surgical treatment were declined. The dog was selected for 
investigational therapy with ICOCAV17.
Treatment and response: physical examination showed a gen-
eral poor body condition and hind leg weakness. Biochemistry and 
hematological analysis were within normal limits. ICOCAV17 was 
injected in four points of the adenoma mass. One day after injec-
tion, mild temporal bleeding in one out of four administration 
points was observed. Fever was detected on day 21 after treatment 
associated to an anal sac abscess which was controlled with broad 
spectrum antibiotics. Biochemistry, coagulation, and hematologi-
cal analysis and physical examination showed no signs of systemic 
toxicity through all the treatment. Tumor progressively decreased 
in size and dysuria disappeared within 3 days after virus adminis-
tration. For at least 6 months, the tumor was in PR with a decrease 
of 51% in size (Figure 5). In the last check-up, 11 months after 
Figure 4 Efficacy and survival after canine adenovirus intratumor injections. Nude mice bearing canine subcutaneous xenografts of osteosar-
coma (Abrams) or melanoma (CML1) were treated with three injections (Day 0, 7, and 14) with phosphate-buffered saline (PBS) or 1 × 1010 viral 
particles per tumor of CAV2, CAV2RGD, ICOCAV15, or ICOCAV17. (a) Mean tumor volume values ± SE are plotted (n = 10–12). (b) Kaplan–Meier 
survival curves. The end point was established at a volume of ≥500 mm3. #Statistical significance between ICOCAV17 and PBS, CAV2, CAV2RGD, and 
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virus inoculation (1 month previous to current submission), pro-
gressive disease was observed with a tumor volume similar to that 
at the start of treatment.
Clinical case II. A 7-year-old entire male Ibizan Warren Hound 
was referred to the Veterinary Hospital with a large humeral 
mass on the right proximal humerus compatible with OS. Owner 
reported that lesions started being evident 1 month before, al-
though normal dog activity had not been compromised until 
1 week before the visit. Humerus fracture and multiple lung me-
tastases were detected by radiography (Figure 6a). Patient pre-
sented with normal appetite, alert status, biochemistry, coagula-
tion, and hematologic profiles, except for an increase in alkaline 
phosphatase. Owner declined euthanasia and conventional treat-
ment protocols. The dog was selected for ICOCAV17 treatment.
Treatment and response: ICOCAV17 was administered using 
echoguidance within four points aiming at the primary tumor, 
although swelling hindered accurate echographic differentia-
tion between normal and tumor tissue. Mild temporary swelling 
with turgor at the injection sites was observed for 48 hours which 
reverted afterwards. No signs of systemic toxicity were noted 
throughout the treatment. Appetite and alert status remained 
unaltered. Tumor size did not show evidence of decrease by echo- 
or radiographic imaging. On day 10 after administration, patient 
showed an open and bleeding wound distal to the administration 
points (Figure 6a). Signs of self-trauma on this site were evident. 
Due to the poor prognosis and the presence of this wound, the 
dog was euthanized. Histopathology examination showed large 
necrotic tumor areas (Figure 6a) around the points of virus 
administration, whereas a nontumor area injected accidentally 
during echoguided administration only showed minimal signs 
Figure 5 Treatment response after a single intratumoral administra-
tion of ICOCAV17 in an infiltrative adenoma canine patient. Patient I 
was admitted to the Veterinary Hospital with urinating problems due to 
a mass in the prepuce skin. Previously excised relapsing adenoma was 
diagnosed. A dose of 1 × 1012 viral particles of ICOCAV17 was adminis-
tered intratumorally (Day 0). At that time, the tumor size was 5.6 × 5 × 
3.5 cm. Six months after treatment, the tumor size had reduced by 51% 
(RECIST) and was 2.9 × 2.8 × 2.2 cm. Tumor size measured by caliper 
(left) and the depth measured by echographic imaging (right) at days 0 
and 180 after treatment, are shown. Right panel: #tumor tissue; *normal 
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of bleeding with lack of necrosis. Moreover, necrotic areas in a 
metastatic nodule of the lung were observed. Virus replication 
was confirmed by immunohistochemistry for Ad late proteins 
in both injected tumor and lung metastasis (Figure 6b). Healthy 
adjacent muscular tissue showed no evidence of virus presence 
(Figure 6b).
Clinical case III. A 7-year-old entire male Labrador Retriever 
was admitted to the Veterinary Hospital with a relapsing cuta-
neous thoracic mast cell tumor confirmed by fine needle aspira-
tion. Conventional chemotherapy (Vinblastine, Prednisone, and 
Lomustine) and tyrosine kinase receptor inhibitor (Toceranib) 
were applied for one and a half month with no response. Tumor 
started bleeding, ulcerated and progressed, reaching a threefold 
volume increase since relapse. The dog was selected for investi-
gational therapy with ICOCAV17. As chemotherapy and hy-
aluronidase synergy has been reported,32,33 and considering the 
fast tumor progression and the experience with the two previous 
cases, Toceranib was used concomitantly to seek chemosensitiza-
tion with hyaluronidase.
Treatment and response: previrus administration; hemato-
logical and biochemical analysis showed mild increase in alanine 
aminotransferase, alkaline phosphatase, anemia, a hematocrit of 
26%, and thrombocytopenia (1.2 × 105 platelets/µl). ICOCAV17 
was injected in 10 different points within the thoracic tumor 
mass. Severe tumor swelling was observed for 48 hours postvi-
rus inoculation. However, tumor necrosis and progressive reduc-
tion in tumor volume were evident from day 3 postinoculation 
until day 10. Hematological and biochemical parameters did 
not change for the first 7 days after virus inoculation, but later 
the patient developed progressive renal and hepatic failure. Due 
to the inflammatory nature of mast cells, the organ failure was 
attributed to the extensive lysis of mast cell tumor cells and the 
prolonged unstable general condition (tumor bleeding with low 
hematocrit and thrombocytopenia). Euthanasia was performed 
10 days after virus administration. At that time, tumor size had 
reduced by 70%. Necropsy showed infarcts in several organs (kid-
neys, liver, spleen, and heart) with petechiae and general jaundice. 
Disseminated intravascular coagulation (DIC) was diagnosed. 
Disseminated intravascular coagulation is a multifactor induced 
pathology common in dogs. Multiple causes such as viremia, sys-
temic inflammatory response, or direct endothelial damage, lead 
to coagulation disorders that can evolve in a disseminated intra-
vascular coagulation.
Clinical case IV. A 7-year-old Golden Retriever entire male, was 
admitted to the Veterinary Hospital with a humeral OS. Limb 
amputation was declined by the owner. Despite treatment with 
conventional chemotherapy, nonsteroidal anti-inflammatory 
drugs, and Toceranib, the disease progressed. Lesions compatible 
with metastases were observed at the shoulder and spinal bone. 
The dog was selected for ICOCAV17 investigational treatment. 
Taking into account the bad prognosis of the patient and the pre-
vious results, a combination with Toceranib was considered.
Treatment and response: Before virus administration, the 
dog presented with hematology and biochemistry profile within 
normal levels, except for mild elevation of alkaline phosphatase. 
After intratumoral administration of ICOCAV17 within the pri-
mary humeral lesion, swelling of injected areas was observed 
followed by a control of tumor growth restricted to the injected 
areas, whereas enlarging of tumor was observed in the surround-
ing areas. No toxicity-related symptoms were observed through 
the treatment. No signs of bioactivity or benefit in terms of quality 
of life were observed and patient was euthanatized 2 months post-
virus injection due to progressive disease. Virus replication could 
not be demonstrated by immunohistochemistry at this time point.
Clinical case V. A 15-year-old Catalan Sheep Dog spayed female 
was admitted to the Veterinary Hospital with a history of right 
leg subcutaneous fibrosarcoma at the distal ulna area, previously 
Figure 6 Histopathology and immunohistochemistry staining of 
healthy tissue, primary tumor, and lung metastasis of an osteosar-
coma patient (Case II). Patient II suffered an osteosarcoma in the right 
front extremity. ICOCAV17 was intratumorally injected in four different 
sites by echoguidance. (a) Euthanasia due to a self-traumatic wound 
(left panel) was performed 11 days after administration. Broad areas of 
necrosis were detected in the primary tumor but also in a lung meta-
static nodule in the anatomopathological study (central and right panel, 
respectively). (b) Ad detection (brown precipitate) was performed by 
immune staining using an anti-adenovirus late protein antibody in depa-
raffinized sections from both, primary and metastatic lesions (central 
and right panel, respectively). A fibrotic barrier (magnified area; white 
arrows) is observed in the tumor. Samples from healthy tissue surround-
ing injected areas were also stained against adenovirus late proteins with 
no Ad detection (left panel). (a and b) Upper panel: original magnifica-
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treated by surgery and radiotherapy. Limb amputation was de-
clined by the owner. Biochemistry and hematology analysis were 
within reference limits and physical examination did not show 
any disorders. Due to the previous case results, in an attempt to 
avoid tumor relapsing and to study virus replication in a short 
time period after virus injection, the dog was selected for investi-
gational treatment in a neoadjuvant setting before surgery.
Treatment and response: ICOCAV17 was inoculated at 
6 points within the tumor. Initial swelling of the tumor was 
observed, followed by tumor progression 10 days after virus injec-
tion. No adverse events were observed. Fifteen days after admin-
istration, tumor was surgically excised. Immunohistochemistry 
showed areas of virus replication in the subcutaneous tumor tissue 
(Figure 7, left panel), although tumor areas without virus replica-
tion were also observed (Figure 7, right panel). The dog recovered 
normally from surgery and after 8 months (last check up, 1 month 
before current submission) she had no evidence of tumor relapse.
Clinical case VI. A 15-year-old small cross bred entire male was 
referred to the Veterinary Hospital with a 2-year history of multi-
ple subcutaneous and hepatic nodules. The treatment with steroi-
dal anti-inflammatory drugs had held the disease stable, however 
tumors were progressing during the last 2 months. Subcutaneous 
nodules on both flanks, below the jaw, and in the cervical area 
were observed. Thoracic radiographs and abdominal ultrasound 
showed nodules on the liver, kidneys, and lungs. A marked al-
kaline phosphatase increase and normal levels of alanine ami-
notransferase were observed on biochemistry, and hematology 
showed a hematocrit of 25.5% and mild nonregenerative anemia.
Treatment and response: Two subcutaneous nodules, one on 
each flank, were injected with 5 × 1011 vp of ICOCAV17 each. 
No adverse effects were observed. Neutrophil count increased 
on day 2, presumably due to mild local reaction. The turgid-
ity of the injected nodules decreased, however, in the last check 
up, only a 14% reduction in tumor volume was observed in one, 
with an increase of 7% in the other. The progression of the dis-
ease led to death of the patient 22 days after administration due 
to cardiac arrest. We were not able to detect virus replication in 
any of the tumors analyzed, however, when the percentage of 
necrotic area was analyzed, a twofold significant increase within 
the injected tumors was observed (Supplementary Figure S2 and 
Supplementary Materials and Methods).
Neutralizing antibodies (Nabs) and virus in whole 
blood and in body secretions
We performed a neutralizing assay using serums from patients 
and canine Ad vector CAVGFP (wild-type capsid) (Table 1). All 
patients, except patient VI, had detectable Nabs against canine Ad 
before treatment, which was expected due to vaccination with CAV-
2. After treatment, Nabs titer progressively increased until the last 
follow-up for all patients except Case V. Virus load in whole blood 
was analyzed by quantitative polymerase chain reaction (PCR) 
(Table 1) (Case III not available). ICOCAV17 was detected early 
after administration and progressively decreased in time, with the 
latest positive samples found 7 days after administration (Cases IV 
and VI). Body secretions (urine, saliva, and feces) were analyzed by 
anti-hexon staining (daily for the first 4 days postadministration). 
No canine Ad infectious particles were detected at any time.
DISCUSSION
The increasing incidence of cancer in dogs requires new thera-
pies that overcome resistance against conventional treatments. 
Herein, we constructed ICOCAV17, a cCRAd based on CAV2 for 
the treatment of a broad spectrum of canine cancers. ICOCAV17 
infected tumor cells more efficiently, showed pRb-mediated 
selectivity, enhanced cytotoxicity in vitro compared with control 
viruses, and inhibited tumor growth in two canine xenografts in 
vivo. Moreover, six canine patients were treated intratumorally. 
No adverse side events directly associated to ICOCAV17 admin-
istration occurred. Two PR and the observation of virus biologi-
cal activity in four out of six cases warrant further studies with 
ICOCAV17. Importantly, the similarities shared by ICOCAV17 
with its human counterpart,19 make it appropriate for extrapo-
lating data from a syngeneic and tumor-spontaneous suffering 
model to humans.
Preclinical characterization showed that RGD-motif insertion 
enhanced infectivity and propagation of CAV2 in three out of four 
cell lines. The effect on infectivity of RGD on CAV2 could not 
be directly extrapolated from previous data with hAds as CAV2 
attaches to and enters cells using a different pathway and lacks 
Figure 7 Immunohistochemistry staining of fibrosarcoma tumor from 
patient V. A Catalan Sheep Dog with a relapsing fibrosarcoma at the dis-
tal ulna area of the right leg was admitted to the Hospital. A neoadjuvant 
setting of virotherapy with ICOCAV17 was performed injecting the virus 
before surgical resection. Tumor was resected 15 days after injection and 
embedded in paraffin. Tumor sections were stained with anti-adenovirus 
late protein antibody. Left panel: virus was detected (brown precipitate) 
in subcutaneous tumor section. Right panel: tumor section staining did 
not result in virus detection. (*) skin, (#) tumor tissue. Upper panel: origi-
nal magnification ×40. Lower panel: original magnification ×200.
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an integrin-interacting motif.34,35 The CAR and integrins influence 
CAV2 trafficking, although exact mechanisms are still unknown. 
We did not find a correlation between CAR-expression levels of 
the cell lines and CAV2 or CAV2RGD infectivity, suggesting, as 
mentioned before,34 the existence of other influencing receptors 
for CAV2. According to the results obtained, the insertion of 
the RGD motif does not inhibit CAR interaction as we did not 
observe a decrease in infectivity in any of the cell lines tested. 
To achieve pRb-E2F-based selectivity,21,36,37 four imperfect palin-
dromic E2F-binding sites and one Sp-I-binding site were inserted 
in the endogenous E1a promoter of CAV2RGD and the pRb-
binding site of E1a was deleted. The homology between hAd5 and 
CAV2 E1 proteins has been previously described.38 The ∆24 dele-
tion in hAd, homologous to the ∆21 deletion in the canine Ad, 
hinders the virus to release cellular E2F from pRb-E2F complexes, 
conferring selectivity for cells with free E2F, which are the major-
ity of tumor cells,37 while restringing viral replication in nonrepli-
cating cells.21 In this study, the E1a-modified promoter increased 
virus burst size and enhanced cytotoxicity in tumor cells, while 
diminished by more than 80% the total virus production in cell 
cycle-arrested nontumor cells. The correlation of pRB status and 
permissiveness to ICOCAV15 supports a pRB-pathway regulation 
similar to ICOVIR15, although coimmunoprecipitation assays 
would be required to demonstrate that pRB does not bind to the 
mutated canine E1a, and that the complex pRB-E2F binds to the 
inserted E2F boxes.
An extracellular matrix rich in HA limits the efficacy of the 
CRAds hindering viral intratumor spread.39 Concentrations of 
HA are elevated in several human40 and canine tumors.41 High 
levels of HA were detected by immunohistochemistry of sec-
tions from CML1 or Abrams xenografts, while 17CM98 tumors 
showed nondetectable HA levels (Supplementary Figure S3 and 
Supplementary Materials and Methods). Human PH20 hyal-
uronidase was inserted instead of isogeneic canine hyaluroni-
dase for two reasons: hPH20 is active at a neutral pH whereas 
canine PH20 exhibits hyaluronidase activity at an acidic pH42 
and CAV2 is already a xenogeneic DNA for the dog. In order 
to link PH20 expression to CAV replication, we inserted the 
human PH20 under the control of the canine IIIa protein splicing 
acceptor which was isolated by sequence alignment with hAd5. 
Thus, ICOCAV17 represents the first armed canine oncolytic 
Ad. In vitro assays did not show any replication impairment for 
ICOCAV17 compared with ICOCAV15. A therapeutic advantage 
for the PH20-armed virus was observed in efficacy studies in two 
canine xenografts. Detection of virus over paraffin-embedded 
tumors was performed at the experiment end point, when animals 
were sacrificed (Supplementary Figure S1 and Supplementary 
Materials and Methods), which may have decreased the possibili-
ties to detect virus. However, a slight increase in the positive area 
of tumors treated with ICOCAV17 compared to the other viruses 
was observed, mainly in Abrams tumors, suggesting an enhanced 
dissemination due to the Hyaluronidase activity.
The toxicity of cCRAds in mice had not been characterized 
before. Herein, canine viruses induced an important systemic 
toxicity with marked thrombocytopenia and body weight loss 
that was aggravated when using RGD-modified viruses. These 
results suggest that the toxicity could be related to the capsid. 
The modifications of the E1a promoter were able to reduce by 
more than 80% the viral production in a cell-cycle arrested cell 
line, but they were not able to reduce systemic toxicity in Balb/C 
mice. Thus, reinforcing the hypothesis of a capsid-related toxicity. 
However, the lack of an antibody against canine E1a hinders the 
possibility to elucidate the impact of E1a in this toxicity. Further, 
contrary to the results obtained in dogs by Smith et al.,18 the biodis-
tribution performed in mice showed no specific liver tropism for 
canine viruses. Moreover, the RGD modified fiber increased the 
presence of virus in some organs and the persistence in blood, sug-
gesting a change in the virus tropism with a slight liver detarget-
ing. A possible explanation might be that CAV2 remains bound to 
mouse blood cells without being so efficiently cleared by the liver 
as are hAds. This could be accentuated for CAV2RGD, thus allow-
ing both viruses to reach multitude of body organs. In whole, these 
results discouraged us to use the intravenous administration route.
Our main aim was to treat canine patients with a fully-repli-
cation competent Ad. Six patients with different tumor types were 
enrolled in an investigational treatment. The dose of 1 × 1012 vp 
per animal administered intratumorally was estimated, using a 
10 times lower dose than a well-tolerated dose in mice adjusted 
by weight. We did not reinject canine patients as we had already 
observed an antitumor response in Case I and III within 3 days 
postadministration. Moreover, 2 × 1012 vp of OCCAV had been 
administered intravenously in dogs with no signs of toxicity.18
Biochemistry, hematology, and coagulation analysis as well 
as physical examination were performed daily for at least 4 days 
after administration. No signs of toxicity associated to ICOCAV17 
were observed, even when virus titers reached 106 vp per milliliter 
of blood. The lytic virus activity in tumors caused adverse side 
events in Case II and III. Case II patient suffered a self-traumatic 
wound, possibly due to the pain induced by the necrotic tumor tis-
sue. Patient III suffered a disseminated intravascular coagulation 
as a result of a prolonged bleeding and a massive tumor lysis. To 
achieve better outcomes, patients with lower tumor loads would 
be desirable and an accurate selection and control of patients with 
proinflammatory tumors should be addressed. The immunohis-
tochemistry of nontumor tissue located near injected sites from 
Case II did not show any evidence of virus replication and no evi-
dence of necrosis in the healthy tissue was detected under mac-
roscopic and microscopic examination. No pathology was found 
in healthy areas of tissue surrounding the injected sites of any 
patient. These findings support the E2F/∆21-conferred selectivity 
observed in vitro and the good tolerance to ICOCAV17 injected 
intratumorally.
RECIST has been questioned to measure virotherapy efficacy43 
as viruses induce tumor swelling, which can be misinterpreted as 
progression. Other criteria, based on health-related quality of 
life,44 or overall survival have been proposed. Efficacy was seen 
in Case I and III with a 51% and 70% of reduction in size, respec-
tively. Benefits of the concomitant treatment in Case III should be 
clarified in future studies. Moreover, a benefit in terms of quality 
of life was clearly observed in Case I where dysuria disappeared 
at day 3. The necrosis associated to viral replication suggests 
virus activity in Case II. While in Case VI, tumor necrosis could 
not be linked to viral replication. Case IV and V did not show 
such a marked benefit, although virus replication was found in 
994 www.moleculartherapy.org vol. 22 no. 5 may 2014
© The American Society of Gene & Cell Therapy
Hyaluronidase-armed Canine Oncolytic Adenovirus
the tumor of patient V. Temporary tumor growth stabilization 
in both patients was observed. The tumor of Patient V was sur-
gically resected 15 days after viral administration. The recovery 
from the surgical procedure was normal and no tumor relapse was 
observed at a follow-up 8 months later. This reinforces the safety 
of the treatment with ICOCAV17 and may suggest a benefit in 
terms of progression-free survival.
Although tumors use multiple pathways to suppress the 
immune system, oncolytic viruses could provide intratumoral 
danger signals that spark an immune response.45 Our most evi-
dent antitumor responses were found in adenoma and mastoci-
toma patient dogs. Whether the benign characteristics of these 
tumors are associated with a lower immunosuppression that 
could facilitate antitumor immunity remains to be studied.
Previous studies suggest that pre-existing immunity against 
the virus may increase the safety of the treatment, while efficacy 
by direct administration may not be inhibited.14,46 Case II had the 
highest Nabs at the baseline but ICOCAV17 induced necrosis in 
the primary tumor and in a metastatic lung lesion. This suggests 
a systemic transport of infective particles even in the presence of 
Nabs. The higher tumor necrosis and viral systemic dissemination 
in Case II compared to Case IV, could be associated to higher cell 
permissiveness to ICOCAV17 replication and the higher accessi-
bility of lung metastasis compared to bone metastases. Recently, 
Factor X has been described to protect hAd5 from Nabs47 but, 
the interaction of CAV2 capsid with canine blood factors remains 
largely unexplored. Levels of Nabs increased progressively until the 
last measurement in all patients except for Case V. This exception 
could be associated to the tumor resection that removed the main 
virus load. Extended presence of virus in blood has been suggested 
as a sign of virus replication. Oncolytic effect was evident for at least 
6 months (Case I), although we were not able to detect viremia later 
than 7 days in any case. Virus load in blood decreased progressively 
in all patients. Therefore, we consider a rapid clearance of circulat-
ing cCRAds from blood. We could not find a correlation between 
virus load in blood, Nabs levels, and antitumor activity or toxicity, 
pointing at permissiveness to CAV replication as a key factor for 
efficacy. Accordingly, IC50 values (Figure 2) suggest a very hetero-
geneous permissiveness to CAV replication. Even when the tumor 
cells came from the same tumor type (Abrams and D17 from OS, 
and CML1 and 17CM98 from melanoma), IC50 values were very 
different. Furthermore, no infectious particles were detected on any 
of the body fluids analyzed, suggesting a low viral leakage from the 
tumor and diminishing the shedding risk. However, special care 
must be undertaken if bleeding or effusions are observed.
In summary, intratumorally treatment of dogs with 
ICOCAV17 was well tolerated and efficacy was observed in an 
infiltrative adenoma and a mast cell tumor. ICOCAV17 replicated 
in tumors and caused tumor necrosis. Enrolling patients with 
less advanced disease could improve efficacy and reduce adverse 
events. Finally, dogs with cancer should be considered as a valu-
able model for human virotherapy.
MATERIALS AND METHODS
Recombinant adenoviruses. Figure 1a shows a schematic diagram outlin-
ing the structure of the viruses used in this study. pTG5412 containing the 
wild-type canine adenovirus serotype 2 (CAV2) genome and CAVGFP,22 
a canine vector expressing green fluorescence protein, were a kind gift 
of Dr Eric Kremer (Institut de Génétique Moléculaire de Montpellier, 
Montpellier, France). We have generated pCAL-CAV2 using a cut and 
repair homologous recombination in yeast.48 pCAL-CAV2 contains the 
CAV2 genome and the elements needed for selection, amplification, and 
homologous recombination in yeast (Saccharomyces cerevisae YPH857). 
To this aim, we amplified CAL,49 a fragment containing the centromere, 
an autonomously replication sequence “ARS”, and a yeast selection gene 
(Leucine), and we inserted two homologue sequences to pTG5412 in 5′ 
and 3′. Next, pTG5412 was partially digested with Not I. pCAL-CAV2 was 
generated by homologous recombination between CAL fragment and the 
partially digested pTG5412.
CAV2RGD has an RGD motif (CDCRGDCFC) inserted in the Hi-
loop (nucleotide position 28110) of the CAV2 fiber. CAV2RGD was 
generated taking advantage of a unique Sal I site present in pCAL-CAV2. 
To this aim, two annealing PCRs were performed. First, the RGD motif 
and a 5′ homologue sequence to pCAL-CAV2 were generated. Then, a 
second PCR to insert a homologue sequence to pCAL-CAV2 in 3′ was 
performed using the product from PCR 1 as a template. By homologous 
recombination, the final product was cloned in Sal I-digested pCAL-
CAV2, generating pCAL-CAV2RGD.
To generate ICOCAV15, a fragment of the CAV2-E1a promoter con-
taining four E2F-binding site hairpins (underlined), one Sp-1 binding site 
(underlined and italics type), and a PmeI restriction site (boldface type) 
(5′-tcggcggctcgtggctctttggcggcaaaaaggatttcgcgcgtaaaagtggttcgaagtactcg 
gcggctcgtggctctttcgcggcaaaaaggatttggcgcgtaaaagtggacagttgtttaaaccgacca 
caaaccccgcccagcgtcttgtcattggcgtcga - 3′) following nucleotide 403 of CAV2 
genome, and a deletion of 21 base pairs (nucleotide positions 818–838), 
was designed and cloned in pUC57 flanked by two Xma I restriction sites 
(GenScript, Piscataway, NJ). A unique Swa I site was used to digest pCAL-
CAV2RGD. Homologous recombination was performed between SwaI di-
gested pCAL-CAV2RGD and the fragment obtained from Xma I digestion 
of pUC57.
To create the PH20 expressing canine adenovirus, a PCR product 
flanked by two homologue sequences downstream ICOCAV15 fiber 
protein and containing the CAV2 IIIa protein splicing acceptor 
(5′-ggccggccctatgaggaagaggagaaccctgatggctccgtctcatttcaacagc - 3′), the 
human PH20 cDNA, and a polyadenilation signal, was generated by 
three annealing reactions and inserted by a cut and repair homologue 
recombination in yeast using the unique Sal I site of pICOCAV15. The 
viral genomic structures were verified by sequence analysis. All viruses 
were generated, plaque purified, and amplified in DK28Cre cells. All 
viruses were purified on CsCl gradients according to standard techniques.
Cell lines. DK28Cre22 cells were a kind gift of Dr Eric Kremer (Institut de 
Génétique Moléculaire de Montpellier). Abrams canine OS cell line and 
17CM98 and CML1 canine melanoma cells were provided by Dr David 
Vail (School of Veterinary Medicine, University of Wisconsin-Madison, 
Wisconsin). D17 canine OS cells were obtained from the American Type 
Culture Collection (Manassas, VA). DEK are an established primary canine 
cell line obtained from CELLnTEC (CELLnTEC Advanced Cell Systems 
AG, Bern, Switzerland). All cells, except DEK, were cultured at 37 °C under 
5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with anti-
biotic solution (100 U/ml penicillin G and 100 U/ml streptomycin) and 5% 
fetal bovine serum. DEKs were cultured at 37 °C under 5% CO2 in CnT-09 
medium from CELLnTEC (CELLnTEC Advanced Cell Systems AG). All 
cells lines were routinely tested for mycoplasma presence.
Protein expression analysis. Cells were seeded in six-well plates. Whole-
cell protein extracts were prepared when tumor-cell cultures reached 
80% of confluence or 20 days after confluence for DEKs by incubation in 
ice-cold radioimmunoprecipitation assay lysis buffer (150 mmol/l NaCl, 
1% Nonidet NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 50 
mmol/l Tris, pH 8.0), containing phenylmethylsulfonylfluoride (1 mmol/l), 
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sodium orthovanidate (1 mmol/l), aprotinin (1%), and leupeptin (20 µg/
ml) for 1 hour at 4 °C. Clarified samples (25 μg/lane) were separated by a 
6.5% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and trans-
ferred to a nitrocellulose membrane (GE Healthcare, Arlington Heights, 
IL). Rb protein detection was performed by immunoblotting membranes 
using a monoclonal anti-Rb primary antibody (Mouse, Clone G3-245; BD 
PharMingen, San Jose, CA) and a sheep anti-mouse antibody conjugated 
with horseradish peroxidase (GE Healthcare, Little Chalfont, UK). A mouse 
monoclonal anti-α-tubulin antibody (Clone DM1A; Sigma-Aldrich, St 
Louis, MO) and a sheep peroxidase-conjugated anti-mouse antibody (GE 
Healthcare) were used for immunoblotting of α-tubulin as a loading control.
Infectivity assay. Abrams or D17 cells (80,000) or 17CM98 or CML1 cells 
(30,000) were seeded in 96-well plates. After 24 hours, cells were infected in 
triplicate with serial dilutions of CAV2 or CAV2RGD, starting from 1,000 
vp per cell. After 24 hours, medium was removed and immune staining 
against hexon protein was performed according to an anti-hexon staining-
based method.17 Infected cells expressing hexon protein were counted in 
the same dilution for both viruses in wells, showing a number of infected 
cells between 10 and 100, the ratio between CAV2RGD and CAV2 was 
calculated in triplicate.
Production assays. The selectivity of ICOCAV15 was measured by com-
paring total production yields in differentiated DEK. DEK become cell-
cycle arrested when they are confluent.28 DEK express cell cycle exit and 
terminal differentiation markers (p21, p27, Involucrin, Loricrin, and Dsg-
1) progressively since they reach confluence.28 DEK were seeded in 24-well 
plates and cultured for 20 days at 37 °C and 5%CO2 with CnT-09. Medium 
was removed thrice a week and fresh medium was added.
For virus production, differentiated DEK were infected with 8 tu/cell, 
CML1, D17 cells were infected with 20 tu/cell, and Abrams and 17CM98 
with 30 tu/cell of each virus to allow for 80 to 100% infection. After 4 
hours, infection medium was removed and cells were washed twice with 
PBS and incubated with fresh medium. Cells and medium (cell extract) 
were harvested 48 hours postinfection and subjected to three rounds of 
freeze-thaw lysis. Viral titers of cell extract were determined in triplicate 
according to an anti-hexon staining-based method17 in DK28Cre cells.
Measurement of CAR expression by flow cytometric analysis. Briefly, 
cell cultures (3 × 105 cells) were incubated with the goat anti-mouse CAR 
polyclonal antibody CXADR according to the manufacturer’s instructions 
(R&D Systems, Minneapolis, MN) at 4 °C for 1 hour. For the visualiza-
tion of the anti-CAR antibody, a second incubation with donkey anti-goat 
Alexa Fluor 488 antibody (diluted 1:300; Invitrogen; Life-technologies, 
Carlsbad, CA) was conducted at room temperature for 1 hour. Cell sam-
ples were analyzed for fluorescence with a Gallios Beckman Coulter flow 
cytometer (Beckman Coulter, Miami, FL) using a 488-nm laser for exci-
tation. All cytometric data were analyzed with FlowJo software (FlowJo. 
7.6.5; Tree Star, Ashland, OR).
Assay for hyaluronidase activity. Hyaluronidase activity assay was per-
formed as described previously.29 In brief, DK28Cre cells were infected 
with 20 tu/cell of each virus to allow for 80 to 100% infection. Four hours 
postinfection, medium was removed and cells incubated with fresh 
medium. After 48 hours, a volume of hyaluronan solution (3 mg/ml) was 
added to the cell medium and cells incubated at 37 °C. After this, at 0, 1, 
2, 3, and 4 hours, aliquots were removed, boiled for 5 minutes, and centri-
fuged. Five volumes of sodium acetate buffer (0.1% bovine serum albumin) 
were added to the supernatant to precipitate hyaluronan. After 10 min-
utes at room temperature, the turbidity was measured at 600 nm. Samples 
with a known concentration of purified hyaluronidase (400, 40, 4, and 
0.4 UI/ml) were used as hyaluronan degradation standard curve.
In vitro cytotoxicity assays. Cytotoxity assays were performed by seed-
ing 20,000 D17 cells, 10,000 Abrams, or 5,000 CML1 or 17CM98 cells 
per well in 96-well plates in Dulbecco’s modified Eagle’s medium with 5% 
fetal bovine serum. Cells were infected with serial dilutions starting with 
2,000 tu/cell for Abrams, 17CM98 or CML1 cells, or 500 tu/cell for D17 
cells. At days 6–8 postinfection, plates were washed with PBS and stained 
for total protein content (bicinchoninic acid assay, Pierce Biotechnology, 
Rockford, IL). Absorbance was quantified and the tu per cell required to 
produce a 50% of inhibition in cell viability (IC50 value) was estimated from 
dose–response curves by standard nonlinear regression (GraFit; Erithacus 
Software, Horley, UK), using an adapted Hill equation.
In vivo toxicity and biodistribution study. Mice for toxicology and efficacy 
studies were maintained at the facility of the ICO-IDIBELL (Barcelona, 
Spain), AAALAC unit 1155. All animal studies have been approved by 
the Institut d’Investigació Biomèdica de Bellvitge Ethical Committee for 
Animal Experimentation. A single dose of 1 × 1011 vp was injected intra-
venously into the tail vein of 8-week-old immunocompetent Balb/C male 
mice in a volume of 150 µl in PBS (n = 5). Daily observations for body 
weight and morbidity were performed. At day 3 postinjection, mice were 
sacrificed, exsanguinated, and samples were collected. Blood samples were 
collected by intracardiac puncture and clinical biochemical and hema-
tological determinations were performed by the Clinical Biochemistry 
and Hematological Services of the Veterinary Faculty at the Autonomous 
University of Barcelona. For biodistribution analysis, organs were frozen 
until processing and DNA was purified following the QIAamp DNA Mini 
Kit (QIAGEN, Valencia, CA) protocol for DNA Purification from tissues. 
DNA from blood was extracted from 200 µl of whole blood using the 
QIAamp DNA Blood Mini Kit (QIAGEN). Purified DNA samples were 
quantified in triplicate by real-time PCR LightCycler480 Roche, using 
the primers (forward primer: 5′-TGTGGGCCTGTGTGATTCCT-3′ and 
reverse primer: 5′-CCAGAATCAGCCTCAGTGCTC-3′), and a Taqman 
probe (FAM-CTCGAATCAGTGTCAGGCTCCGCA-TAMRA), which 
identify E1A region. Virus loads were calculated using LightCycler v4.05 
software (Roche, Basel, Switzerland) and a regression standard curve 
based on serial dilutions of pCAL-CAV (1 × 107 to 1 vp/µl).
Evaluation of in vivo antitumoral efficacy. Subcutaneous Abrams or 
CML1 canine tumors were established by injection of 2 × 106 cells into the 
flanks of 6-week-old female Balb/c nu/nu mice. Once tumors reached the 
desired mean tumor volume (100 mm3 for Abrams tumors and 150 mm3 for 
CML1 tumors), mice were randomly distributed into treatment groups (n = 
10–12 tumors per group) and treated (experimental day 0) with an intratu-
moral injection at days 0, 7, and 14 with 25 µl of PBS or 1 × 1010 vp of CAV2, 
CAV2RGD, ICOCAV15, or ICOCAV17 in a volume of 25 µl in PBS. Mice 
status was monitored daily during the 3 days after virus administration. 
Tumor size and mice status were monitored twice a week. Tumor volume 
was defined by the equation V (mm3) = π/6 × W2 × L, where W and L are the 
width and the length of the tumor, respectively. When animals from each 
group displayed uncontrolled tumor growth, the mice were euthanized.
For Kaplan–Meier survival curves, end point was established at 
tumor volume of ≥500 mm3. The survival curves obtained were compared 
for the different treatments. Animals whose tumor size never achieved 
the maximum allowed size were included as right censored information.
Patients. Patients with advanced solid tumors (Table 1) refractory to con-
ventional treatments or with a bad prognosis under routinely protocols 
were eligible for oncolytic virotherapy with ICOCAV17. The inclusion 
criteria were solid, accessible tumors, refractory or with a bad expected 
response to conventional therapies and no major organ functions defi-
ciencies. Specific exclusion criteria were immune suppressed animals, 
with liver disease (hyperbilirubinemia, threefold or higher elevated liver 
enzymes), thrombocytopenia (<1 × 105 Plt/µl), hematocrit < 25%, or car-
diorespiratory dysfunctions.
Treatment protocol. ICOCAV17 therapy was approved by the Small 
Animal Internal Medicine Department of the Veterinary Teaching Hospital 
(Fundació Hospital Clinic Veterinari) of the Autonomous University of 
Barcelona. Informed consent was obtained from the dog owners.
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Once patients were accepted for treatment with oncolytic virus, 
on the day of treatment, they were isolated in a facility approved for 
virus administration in the fundació Hospital Clinic Veterinari of the 
Autonomous University of Barcelona. Animals were isolated until day 4 
after virus administration. Tumors were divided in equal in size quadrants 
and dose was distributed equally. All patients received a single echoguided 
intratumoral total dose of 1 × 1012 vp of ICOCAV17 diluted in 1 mililiter 
of sterile PBS. General anesthesia or sedation with local anesthesia was 
used according to veterinary recommendation. In Case I, II, and VI, no 
other agents rather than antibiotics or palliative unrelated agents were 
given. In Case III and IV, concomitant treatment with the same previously 
administered chemotherapeutic agents was performed (Table 1). Patient 
V was not concomitantly treated with chemotherapy although surgical 
resection procedure was included on the protocol before starting the 
treatment.
Monitoring of patients. Patients were monitored daily for the first 4 days. 
Attitude, appetite, temperature, cardiac and respiratory frequency, and 
tumor appearance were checked every 8 hours. Biochemical, hematologic, 
and coagulation (prothrombin time, partial thromboplastin time, and 
fibrinogen) analysis were performed once a day, as well as blood, urine, 
saliva, and fecal sampling. After hospitalization, differences in sampling 
schedule were adapted to practical issues related to owner time availability. 
In Case III, the patient was held in observation through the whole process 
due to its hematologic disorders and evident tumor lysis from day 3. Tumor 
size was assessed by a caliper and echographic imaging. Maximum tumor 
diameters were calculated according to RECIST v1.1 (ref. 50): complete 
response (CR; undetectable tumor after treatment), PR (≥ 30% reduction 
in the sum of tumor diameters), stable disease (no reduction or increase), 
and progressive disease (≥ 20% increase in tumor size).
Analysis of viral infective particles from body secretions. Samples from 
saliva were obtained using the Salivette system (Sarstedt, Numbrecht, 
Germany). Samples from urine were obtained using a urinary catheter 
or intravesical injection. Samples of feces were obtained from the rectum. 
All samples were frozen until processing. The fecal samples were diluted 
1/100 W/V in PBS with penicillin and streptomycin and homogenized. 
Before titering, samples were centrifuged (10,000g for 10’). Once centri-
fuged, viral titers were determined in triplicate according to an anti-hexon 
staining-based method17 in DK28Cre cells. Limits of detection were 100 
tu/ml of urine or saliva and 10,000 tu/g of feces.
Histopathology and immunohistochemistry. Samples obtained from 
tumor or healthy tissues (Case II, IV, V, and VI) were fixed in 10% buffered 
paraformaldehyde for 24 hours and embedded in paraffin. Routine hema-
toxylin-eosin staining and immunohistochemistry against adenovirus late 
proteins were performed. Blocks were cut into 4-µm thick sections and 
were deparaffinized, endogenous peroxidase activity blocked, and antigen 
retrieval was performed in citrate buffer. After rehydration, sections were 
blocked for 30 minutes with 20% normal horse serum diluted in PBS 1% 
bovine serum albumin. Samples were incubated with rabbit anti-late ade-
novirus proteins polyclonal IgG (Ab6982 Abcam; cross reactivity against 
CAV2)17 overnight at 4 °C. Slides were washed thrice in PBS 0.2% Triton 
X-100 and incubated with EnVision (Dako, Hamburg, Germany) accord-
ing to the manufacturer’s instructions. After washing, sections were devel-
oped with diaminobenzidine (Dako Laboratories, Glostrup, Denmark) 
and counterstained with hematoxylin. Images of sections were captured on 
a Nikon Eclipse 80i microscope (Nikon Instruments), using the software 
NIS-Element Basic Research 3.2 (Nikon, Melville, NY).
Neutralizing antibody titer determination. Samples of serum were heated 
at 56 °C for 30 minutes in order to inactivate complement. Serial dilutions 
of inactivated samples were performed in free-serum Dulbecco’s modified 
Eagle’s medium in 96-well plates in triplicate, starting from 1/10 (limit of 
detection) for low titer samples to 1/1,000 for high titer samples. A volume 
of 100 µl containing 1 × 105 tu of CAVGFP, was added to each well and 
incubated for 1 hour at room temperature. Afterwards, 5 × 104 DK28Cre 
cells per well were seeded and cultured overnight at 37 °C and 5% CO2. The 
neutralizing antibody titer was determined as the lowest degree of dilution 
that inhibited the cell transduction by more than 50%.
Quantitative real-time PCR for presence of ICOCAV17 in whole blood 
samples. DNA was extracted from 200 µl of whole blood using the 
QIAamp DNA Blood Mini Kit (QIAGEN). Purified DNA samples were 
quantified in triplicate by real-time PCR LightCycler480 Roche, using 
the primers (forward primer: 5′-TGTGGGCCTGTGTGATTCCT-3′ and 
reverse primer: 5′-CCAGAATCAGCCTCAGTGCTC-3′), and a Taqman 
probe (FAM-CTCGAATCAGTGTCAGGCTCCGCA-TAMRA), which 
identifies E1A region. Virus loads were calculated using LightCycler v4.05 
software and a regression standard curve based on serial dilutions of 
pICOCAV17 (1 × 107 to 1 vp/µl). The limit of quantification for the assay 
was 500 vp/ml.
Statistical analysis. Statistics were done with SPSS 13.0 software (IBM, 
Armonk, NY). Two-tailed Student’s unpaired t-test was used to compare 
data, except for survival analysis when data was processed with Kaplan–
Meyer analysis.
SUPPLEMENTARY MATERIAL
Figure S1. Immunohistochemistry of tumors from in vivo efficacy as-
says in Abrams and CML1 models.
Figure S2. Hematoxilin & Eosin staining of tumors from patient VI.
Figure S3. Hyaluronic acid detection within three canine xenografts 
tumors.
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